Moderna's Stock Rises on Strong Momentum from Cancer Vaccine Data
Moderna (NASDAQ:MRNA) saw its stock climb by approximately 6% in morning trading, extending a remarkable one-month gain of 137%. This surge is attributed to the strong Phase 2b melanoma vaccine data presented at ASCO 2026. The results showed that combining intismeran autogene with Merck’s KEYTRUDA reduced recurrence risk by 49% compared to KEYTRUDA alone. The market appears focused on Moderna's specific asset rather than the broader mRNA cancer vaccine category, as evidenced by a muted response from BioNTech (NASDAQ:BNTX), which is up just 1%. The next major milestone for Moderna will be an interim analysis of its Phase 3 adjuvant melanoma trial expected in late 2026. Madrid’s oncology congress later this year could provide the first public data update. The broader biotech sector and S&P 500 ETF are also up modestly, but Moderna's performance is largely self-driven without new disclosures or announcements.
Tickers: $BNTX $MRK $MRNA $NVAX
Topics: cancer vaccine Moderna mRNA therapy Phase 2b data stock rally